CDX2 expression in cutaneous metastatic carcinomas and extramammary Paget's Disease. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Anticancer Research Année : 2009

CDX2 expression in cutaneous metastatic carcinomas and extramammary Paget's Disease.

Résumé

BACKGROUND: CDX2 is a gene involved in the regulation of intestinal cell proliferation/differentiation. It is considered specific for enterocytes and has been used for the diagnosis of primary and metastatic colon adenocarcinoma. The aim of this study was to assess the usefulness of CDX2 in the diagnosis of cutaneous metastatic tumors and extramammary Paget's disease. MATERIALS AND METHODS: The immunohistochemical expression of CDX2 was studied in 68 cutaneous metastatic tumors of various origins and 14 specimens of extramammary Paget's disease. RESULTS: CDX2 expression was found in 3/6 metastases of colon adenocarcinoma, 1/1 metastasis of urothelial carcinoma and 1/2 extramammary Paget's disease. CONCLUSION: CDX2 appears to be specific for cutaneous metastases from intestinal and urothelial carcinomas and is a useful diagnostic marker of these tumors. However, its sensitivity is modest, and we advocate its use in conjunction with additional immunohistochemical markers. CDX2 seems useful for the diagnosis of extramammary Paget's disease associated with an underlying colorectal tumor.

Domaines

Dermatologie
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-00462238 , version 1 (08-03-2010)

Identifiants

  • HAL Id : inserm-00462238 , version 1
  • PUBMED : 20044613

Citer

Viviana Lora, Jean Kanitakis. CDX2 expression in cutaneous metastatic carcinomas and extramammary Paget's Disease.. Anticancer Research, 2009, 29 (12), pp.5033-7. ⟨inserm-00462238⟩

Collections

INSERM HCL HEH
113 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More